




14 Open Doctoral Positions – ENTRY-DM

European Union Funded MSCA Doctoral Network

Advancing Therapeutic Development for Myotonic Dystrophy



About the ENTRY-DM Network



ENTRY-DM is recruiting **14 full-time doctoral candidates** to advance innovative therapies for **myotonic dystrophy (DM)**.

This EU-funded Doctoral Network brings together leading international experts in **DM research, antisense oligonucleotide (ASO) therapies, bioengineering and clinical trials**, creating a dynamic and collaborative training environment.

We will train a new generation of researchers across academia, industry and clinical sectors, to push the frontiers of ASO development and technology transfer.





























Be part of a pioneering effort to transform the future of DM therapy.








Why Join?

- **Interdisciplinary training** in disease modelling, molecular mechanisms, ASO design, drug delivery, and clinical trials.
- **Hands-on experience** in fundamental research, bioengineering, clinical assessments, and neuropsychological evaluation.
- Collaborate with leading experts from academia and industry through extensive **international mobility**.
- **Two short-term secondments** (3-month visits) to international and intersectoral partner labs within the consortium.
- Access to **state-of-the-art labs, cutting-edge research** and **top-level training**, delivered through *in person* and online events led by world experts in the field. Participation in **international conferences** in the field.
- **Full-time contracts** with attractive Marie Skłodowska-Curie salaries, including social security and family allowances.
- **Boost your career prospects** in worldwide research and therapeutic development, whether in **academia or industry**.

Eligibility criteria

- Motivated and talented candidates **from all nationalities** with a strong fundamental or clinical background in **biomedical sciences, bioengineering**, or related fields are encouraged to apply. **Application deadline May 30, 2025.**
- **Please ensure that you comply with EU eligibility and mobility conditions** before applying.
- Ready to make an impact in rare disease research? **Apply now at the links below!**

Country	Project title	Supervisor	Host	Secondments
DC1 	Innovative genomic technologies for the advanced characterization of DM mutations	Marzia Rossato	Genartis Verona, Italy	Rome, IT Paris, FR 
DC2 	The complexity of DM repeat expansions: new challenges in developing personalised molecular therapeutics	Annalisa Botta	Universita di Roma Tor Vergata Rome, Italy	Verona, IT Nijmegen, NL 
DC3 	A new integrated in vitro platform to study DM muscle disease	Javier Ramon	Institute Bioengineering of Catalonia Barcelona, Spain	Paris, FR Cambridge, USA 
DC4 	Advanced human 3D neuromuscular and cortical models for mechanistic and therapeutic research	Cécile Martinat	I-Stem Evry, France	Rome, IT Nijmegen, NL 
DC5 	Structure and dynamics of nuclear RNA foci in DM1 and DM2	Rick Wansink	Radboud University Nijmegen, The Netherlands	Valencia, ES Evry, FR 
DC6 	The contribution of miRNome alterations to DM1: beyond the Muscleblind sequestration model	Rubén Artero	University of Valencia Valencia, Spain	Poznań, PL Valencia, ES 
DC7 	Rescuing disrupted single-cell and neural network activities in human DM neural models using ASO	Hans van Bokhoven	Radboud University Nijmegen, The Netherlands	Cambridge, USA Richmond, USA 
DC8 	Therapeutical potential of ASO inducing skipping of CUGexp-containing exon in DM	Krzysztof Sobczak	Adam Mickiewicz University Poznań, Poland	Evry, FR Oxford, UK 
DC9 	Enhancing the activity of therapeutic ASO by genetic modulation and sequence motif adjuvants	Arturo Lopez-Castel	University of Valencia Valencia, Spain	Nijmegen, NL Evry, FR 
DC10 	Novel ASO molecules for the therapy of DM1	Carme Fàbrega	Spanish National Research Council Barcelona, Spain	Oxford, UK Evry, FR 
DC11 	Development of circulating muscle-specific biomarkers of myotonic dystrophy	Geneviève Gourdon	Inserm, Centre of Research in Myology Paris, France	Valencia, ES Munich, DE 
DC12 	Circulating biomarkers of brain dysfunction in DM1	Mario Gomes-Pereira	Inserm, Centre of Research in Myology Paris, France	Valencia, ES Gainesville, USA 
DC13 	DM2: Biomarker discovery and correlation to clinical outcomes	Benedikt Schoser	Ludwig Maximilian University of Munich Munich, Germany	Verona, IT Barcelona, ES 
DC14 	Participation in clinical trials: the contribution of decision-making cognition in patients with DM1	Nathalie Angeard	Paris City University Paris, France	Paris, FR Gothenburg, SE 

Training Events	Topic	Location	Date
Conference #1	Introduction to DM	Paris, FR 	Jan 2026
Online #1	Research management & ethics	Online 	May 2026
Conference #2	Entrepreneurship & technology transfer	Valencia, ES 	Feb 2027
Online #2	Bioinformatics	Online 	May 2027
Conference #3	Translational medicine	Nijmegen, NL 	Nov 2027
Online #3	Clinical preparedness	Online 	Feb 2028
Conference #4	Final conference & job fair	Paris, FR 	Jun 2028
Continuous online and local training on sustainable laboratories; market and R&D updates from pharmaceutical partners; ongoing clinical trials; the PhD after life; research integrity...			

Eligibility criteria Application procedure



 <https://www.entry-dm.eu>